Hans Eriksson, MD, PhD profile page

Chief Medical Officer

at Fundamental Pharma

Dr. Hans Eriksson is a psychiatrist with more than 25 years of experience in drug development. He has led clinical development programs at AstraZeneca, Lundbeck, COMPASS Pathways, and HMNC Brain Health.

He has contributed to eight late-phase clinical development programs in depression, three of which resulted in regulatory approvals for major depressive disorder.

Education

Lund University

Stockholm School of Economics

Got a Question for Hans Eriksson, MD, PhD?

Get in touch using the contact form linked here and we'll get back to you shortly.

Content Written By, Reviewed By, or Featuring Hans Eriksson, MD, PhD

Total: 1

Mid-section of a person pouring white pills from an orange container into their hand.

Industry Insight

Investigational Drug Could Provide At-Home Treatment-Resistant Depression Care

FMP374 is a dual-acting NMDA modulator aiming to overcome challenges with older NMDA antagonists. In preclinical TRD models, it showed rapid antidepressant effects with fewer side effect signals, supporting continued development.